Innate Pharma S.A Stock (NASDAQ:IPHA)

USA |NASDAQ |USD |ADR

Price
$5.29
Change
1.93%
Today's Range
$5.19 - $5.35
52-Week Range
$3.02 - $8.20
Market Cap
$419.55M
Volume
34.20K

About Innate Pharma S.A (NASDAQ:IPHA)

(NASDAQ:IPHA) Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal cancer, as well as head and neck cancer; Anti-Siglec-9, checkpoint inhibitor program, which is in preclinical stage for immuno-oncology; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; and Lacutamab (IPH4102), an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma. Its products also include IPH61, a bispecific NK cell engager, a preclinical solution for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, a program that is in preclinical trial to develop anti-MICA/B therapeutic antibody in oncology; Avdoralimab/IPH5401, a therapeutic antibody, which is in Phase II clinical trial that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils; IPH5201, a blocking antibody that is in Phase I clinical trial targeting the CD39 immunosuppressive pathway; and IPH5301, a CD-73-blocking antibody that is in preclinical trial for restoring a pro-inflammatory microenvironment. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, and Sanofi; and co-development and license agreement with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.
Show more

IPHA Stock Price

Statistics Highlights (NASDAQ:IPHA)

Shares Outstanding 79.31M Beta -0.17
Public Float 51.04M P/E Ratio -
% Short of Float - Dividend (Yield) -
Held by Insiders - Ex-Dividend Date
Held by Institutions 0.45% IPO Date Oct 17, 2019

IPHA Financial Summary

|
Dec 20 Dec 19 Dec 18
Revenue $56.83M $68.97M $79.89M
EBITDA $38.81M $-8.88M $10.22M
Net Income $-63.98M $-20.76M $3.05M
Total Assets $307.42M $401.36M $451.22M
Total Cash $136.79M $202.89M $152.31M
Total Debt $19.09M $18.72M $4.52M
Jun 21 Mar 21 Dec 20
Revenue $ $ $
EBITDA $ $ $
Net Income $ $ $
Total Assets $266.22M $ $307.42M
Total Cash $103.98M $ $136.79M
Total Debt $16.50M $ $19.09M

IPHA Stock Price History

Innate Pharma S.A Annual Stock Price History

Year Open Close Change
2022 $4.67 $5.29 13.28%
2021 $4.19 $4.67 11.46%
2020 $6.43 $4.19 -34.84%

Innate Pharma S.A Daily Stock Price History

Date Open High Low Close Change Volume
Jan 21, 2022 $4.25 $4.28 $4.12 $4.12 -7.00% 21.81K

(NASDAQ:IPHA) Stock Price FAQs

What is today's stock price of Innate Pharma S.A (NASDAQ:IPHA)?

  • The current stock price of Innate Pharma S.A (NASDAQ:IPHA) is $5.29.
  • Today IPHA stock price opened at $5.31 after previous close of $5.19.
  • During the day, Innate Pharma S.A stock quote has varied from a low of $5.19 to a high of $5.35.

What is Innate Pharma S.A's 52-week change?

  • IPHA 52-week high stock quote is $8.20, which is 55.00% above the current share price.
  • The Innate Pharma S.A (NASDAQ:IPHA) 52-week low stock price is $3.02, which is 42.90% below the current share price.
  • Innate Pharma S.A share price volatility (52-week beta) is -0.17.

Is Innate Pharma S.A a buy?

  • According to 5 analysts, the current consensus recommendation for Innate Pharma S.A stock is "Buy" at an average rating score of 4.40 (out of 5).
  • There are currently 3 "Strong Buy", 1 "Buy", 1 "Hold", 0 "Sell", and 0 "Strong Sell" analysts recommendations for the IPHA stock.
  • The 12 month average price target forecast for IPHA stock is $8.45, representing a 59.70% increase from the current IPHA stock price of $5.29.

Innate Pharma S.A (NASDAQ:IPHA) FAQ

How Much is Innate pharma s.a Worth?

Innate pharma s.a's worth today based on market capitalisation is $419.55M

How much dividend does Innate pharma s.a Pay?

The current annualized dividend payout for IPHA stock is $0.00, the dividend yield is 0.00% and the payout ratio is 0.00%.
View More Details on Innate pharma s.a's "Dividend" Section

What is Innate pharma s.a’s Price to Earning (PE) ratio?

IPHA stock also has a Price to Sales (P/S) ratio of 8.49.

What is the Innate pharma s.a's ticker?

Innate pharma s.a trades on the NASDAQ stock market in USA under the ticker symbol "IPHA". Innate pharma s.a’s stock symbol can also be displayed as "NASDAQ:IPHA".

When did IPHA go public?

Innate pharma s.a completed its initial public offering (IPO) on October 17 ,2019.

Who are the owners of Innate pharma s.a?

Innate pharma s.a (NASDAQ:IPHA) is owned by 0.45% institutional shareholders and by 0.00% insiders. The rest is owned by the public.
The 3 top institutional shareholders are "Millennium Management LLC", "Morgan Stanley - Brokerage Accounts" and "Optiver Holding B.V.", representing 0.11% of Innate pharma s.a’s total shares outstanding.
Explore More Details on Innate pharma s.a's “Ownership” Section

Who are the key executives of Innate pharma s.a (IPHA)?

Innate pharma s.a's key executive team includes the following managers:

  • Dr. Mondher Mahjoubi, Chairman of Exec. Board & CEO (1958)
  • Mr. Yannis Morel, Exec. VP of Product Portfolio Strategy & Bus. Devel. and Member of Exec. Board (1973)
  • Ms. Laure-Helene Mercier M.B.A., M.Sc., MSc, MBA, Exec. VP of Fin. & Corp. Strategy (1978)
  • Dr. Herve Brailly, Co-Founder & Chairman of Supervisory Board (1961)
  • Dr. François Romagné, Founder (1964)
  • Mr. Eric Vivier D.V.M., M.B.A., Ph.D., Founder, Sr. VP & Chief Scientific Officer (1964)
  • Dr. Marc Bonneville Ph.D., Founder (1960)
  • Mr. Jean Jacques Fournié Ph.D., Founder (NA)
  • Mr. Alessandro Moretta M.D., Ph.D., Founder (NA)
  • Mr. Frederic Lombard M.B.A., Sr. VP & CFO (NA)

What is Innate pharma s.a’s Sector & Industry Classification?

Innate pharma s.a (NASDAQ:IPHA) is classified under the "Healthcare" sector and under the "Biotechnology" industry.

How many employees work for Innate pharma s.a?

Currently the number of employees working for Innate pharma s.a is 212.

Where are Innate pharma s.a's Headquarters?

Innate pharma s.a (NASDAQ:IPHA) is headquartered in France.

What are Innate pharma s.a's Address and Phone Number?

Innate pharma s.a’s mailing address is 117, Avenue de Luminy, Marseille, France, 13009.
The company’s phone number is 33 4 30 30 30 30.

What is the official website for Innate pharma s.a?

Innate pharma s.a’s official website is http://www.innate-pharma.com